The purpose of this study was to determine the influence of hydrochloric acid on surface roughness of composite resins subjected to brushing. Sixty samples measuring 2 mm thick x 6 mm diameter were prepared and used as experimental units. The study presented a 3x2 factorial design, in which the factors were composite resin (n=20), at 3 levels: microhybrid composite (Z100), nanofilled composite ...

MICs of tigecycline determined by Etest were 4 to 12 times (three ATCC strains) and 2 to 8 times (50 clinical isolates) higher in Mueller-Hinton agar from Merck than in Mueller-Hinton agar from either Oxoid or Difco. This was related to a much higher concentration of manganese in the medium from Merck.

The chemical potentials of each solute in an aqueous mixture of two electrolytes have been determined for many systems. For example, the activity coefficients of both hydrochloric acid and sodium chloride in mixed aqueous solution have been derived from emf measurements [I]. The isopiestic vapor pressure method has been used [2] to determine the activity coefficients of each solute in aqueous m...

Canada Research Chair on Electroactive a Chemistry, Université Laval, Quebec City, Q [email protected] Department of Chemistry, Université Laval, Department of Chemical Engineering, Unive 3G1, Canada Merck Chemicals Ltd, Chilworth Technical Merck KGaA, Darmstadt, Germany) † Electronic supplementary information 1507661. For ESI and crystallographic dat DOI: 10.1039/c7sc00589j ‡ T. Bura and S...

Employment or Leadership: None declared. Consultant or Advisory Role: None declared. Stock Ownership: None declared. Honoraria: E. Giannitsis, Merck Sharp & Dohme, Lilly, Bristol Myers Squibb, GlaxoSmithKline, Roche Diagnostics, and Bayer; H.J. Roth, Merck Sharp & Dohme and Roche Diagnostics. Research Funding: E. Giannitsis received funds and access to assays from Roche Diagnostics. Expert Test...

Funding Editorial support was funded by Sanofi and Regeneron Pharmaceuticals, Inc. Conflict of interest: G.K.H.: none declared; M.H.D.: acted as consultant/advisory board member for Amgen, AstraZeneca, Merck, and Sanofi-Aventis and a stockholder in Omthera Pharmaceuticals, Inc.; J.J.P.K.: a consultant to Regeneron, Sanofi, Eli Lilly, Amgen, Aegerion, Merck, Isis, Genzyme, Novartis, Kowa; A.M.O....

Potential conflicts of interest.D.R.K. has served as a consultant for and has received speaker’s fees and research support from Boehringer-Ingelheim, Bristol-Myers Squibb, and GlaxoSmithKline. R.M.G. has received research grants (awarded to Cornell University) from Merck and has served as an ad hoc consultant to BoehringerIngelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, and Merck. All ...